Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PERKINELMER, INC.

(PKI)
  Report
Delayed Nyse  -  04:03:16 2023-02-07 pm EST
139.50 USD   +1.16%
01/26PerkinElmer Board Declares Quarterly Dividend
BU
01/26PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023
CI
01/24Barclays Adjusts PerkinElmer's Price Target to $140 From $145, Maintains Equal Weight Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/01/2023 02/02/2023 02/03/2023 02/06/2023 02/07/2023 Date
139.27(c) 144.38(c) 141.75(c) 137.9(c) 139.5 Last
1 238 224 933 579 756 033 528 362 569 872 Volume
+1.27% +3.67% -1.82% -2.72% +1.16% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4 594 M - -
Net income 2022 583 M - -
Net Debt 2022 3 708 M - -
P/E ratio 2022 30,1x
Yield 2022 0,20%
Sales 2023 3 116 M - -
Net income 2023 484 M - -
Net Debt 2023 1 056 M - -
P/E ratio 2023 36,5x
Yield 2023 0,20%
Capitalization 17 621 M 17 621 M -
EV / Sales 2022 4,64x
EV / Sales 2023 5,99x
Nbr of Employees 16 700
Free-Float 99,8%
More Financials
Company
PerkinElmer, Inc. specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales break down by family of products as follows : - medical diagnosis equipments (57.9%); - analytical tools and instruments (42.1%): biological molecular research tools, thermal analysis software, chemical... 
More about the company
Ratings of PerkinElmer, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about PERKINELMER, INC.
01/26PerkinElmer Board Declares Quarterly Dividend
BU
01/26PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023
CI
01/24Barclays Adjusts PerkinElmer's Price Target to $140 From $145, Maintains Equal Weight R..
MT
01/19PERKINELMER, INC. : Ex-dividend day for
FA
01/10Perkinelmer : Non-GAAP Reconciliations
PU
01/10Perkinelmer : J.P. Morgan 41st Healthcare Conference Presentation
PU
01/10Perkinelmer : 2023 JPM Healthcare Conference Presentation
PU
01/10Transcript : PerkinElmer, Inc. Presents at 41st Annual J.P. Morgan Healthcare..
CI
01/10PerkinElmer Expects to Meet or Exceed Previous Q4 Guidance
MT
01/09Perkinelmer Inc : Results of Operations and Financial Condition (form 8-K)
AQ
01/09PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter..
BU
01/09PerkinElmer, Inc. Revises Earnings Guidance for the Fourth Quarter 2022
CI
2022Insider Sell: Perkinelmer
MT
2022Insider Sell: Perkinelmer
MT
2022North American Morning Briefing: Futures Waver -2-
DJ
More news
News in other languages on PERKINELMER, INC.
01/26PerkinElmer, Inc. Déclare un dividende trimestriel régulier, payable le 12 mai 2023
01/10PerkinElmer prévoit d'atteindre ou de dépasser ses prévisions pour le quatrième trimest..
01/09PerkinElmer, Inc. révise ses prévisions de résultats pour le quatrième trimestre 2022
2022Vente d'initiés : Perkinelmer
2022Vente d'initiés : Perkinelmer
More news
Analyst Recommendations on PERKINELMER, INC.
More recommendations
ETFs positioned on PERKINELMER, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
The Cannabis ETF - Acc - USD3.21%5.11%-World
Xtrackers MSCI Genomic Healthcare Innovatio...1.78%1.02%-NC
Pacer US Cash Cows Growth ETF - USD1.76%-1.50%NC
Invesco S&P 500� Pure Growth ETF - USD1.67%0.07%United_States
Robo Global Healthcare Technology and Innov...1.48%3.48%World
More ETFs positioned on PERKINELMER, INC.
Chart PERKINELMER, INC.
Duration : Period :
PerkinElmer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERKINELMER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 139,50 $
Average target price 160,00 $
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Prahlad Ramadhar Singh Senior Vice President & President-Diagnostics
Maxwell Krakowiak Senior Director-Commercial Finance
Alexis Platon Michas Non-Executive Chairman
Tajinder S. Vohra Vice President-Global Operations
Joel S. Goldberg Secretary, SVP-Administration & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
PERKINELMER, INC.-1.65%17 419
THERMO FISHER SCIENTIFIC4.63%227 039
DANAHER CORPORATION-0.63%192 089
INTUITIVE SURGICAL, INC.-6.17%87 986
BOSTON SCIENTIFIC CORPORATION4.82%68 264
SIEMENS HEALTHINEERS AG12.82%63 361